Bevacizumab

Basic Information


CAS ID: 216974-75-3
Molecular Formula:
Molecular Weight: g/mol
Monoisotopic Mass: g/mol
Class: Monoclonal antibody
Natural Product: No
Other Names: RHUMAB-VEGF | R-435 | 12-IGG1 | RG-435 | BEVACIZUMAB | AVASTIN
Analysis: N/A


Compound Structure and Identifier


InChI: See All
InChI Key:
Smiles: See All
Molfile:


Related Target



Related Fibrosis Property


Trial Record 1

ClinicalTrial ID NCT01917877 Disease Pulmonary fibrosis
Phase Phase 2 Status Recruiting
First Received August 7, 2013 Last Verified February 14, 2018
Sponsor Qingdao Central Hospital

Trial Record 2

ClinicalTrial ID NCT01166594 Disease Fibrosis
Phase Phase 4 Status Completed
First Received July 21, 2010 Last Verified February 19, 2015
Sponsor Sunnybrook Health Sciences Centre

Trial Record 3

ClinicalTrial ID NCT00854529 Disease Bleb fibrosis
Phase Phase 2 Status Unknown
First Received March 3, 2009 Last Verified March 3, 2009
Sponsor Rabin Medical Center

Trial Record 4

ClinicalTrial ID NCT02591914 Disease Subfoveal fibrosis
Phase Phase 1 Status Completed
First Received October 30, 2015 Last Verified September 24, 2018
Sponsor Retinal Consultants of Arizona

Trial Record 5

ClinicalTrial ID NCT00815594 Disease Scar
Phase Phase 4 Status Unknown
First Received December 30, 2008 Last Verified December 30, 2008
Sponsor Capital Medical University

Trial Record 6

ClinicalTrial ID NCT03095001 Disease Peritoneal fibrosis
Phase Phase 2 Status Recruiting
First Received March 29, 2017 Last Verified April 13, 2017
Sponsor Chinese PLA General Hospital

Trial Record 7

ClinicalTrial ID NCT01408953 Disease Keloid
Phase Phase 2 Status Terminated
First Received August 3, 2011 Last Verified October 18, 2016
Sponsor Tirgan, Michael H., M.D.

Trial Record 8

ClinicalTrial ID NCT00667277 Disease Bone marrow fibrosis
Phase Phase 2 Status Terminated
First Received April 28, 2008 Last Verified August 22, 2014
Sponsor Ronald Hoffman

Related Link


PubChem: 47208066
ChEMBL: CHEMBL1201583